Bone Biologics Corp (BBLG) News
Filter BBLG News Items
BBLG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BBLG News From Around the Web
Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.
BBLG in Good Shape as Testing ContinuesBy Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 3Q 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing nicely, the financial picture is also vital. This quarter’s release shows that the company has made further advances in |
Bone Biologics Appoints Phillip T. Meikle to its Board of DirectorsBURLINGTON, Mass., October 21, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. |
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBURLINGTON, Mass., September 04, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics’ company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern t |
LifeNet launches newest bone allograft gel with Johnson & JohnsonDesigned in Virginia and commericalised by Johnson & Johnson, Lifenet Health’s bone allograft is aims to help surgeons expedite procedures. |
BBLG: Controls Costs and Advances TrialsBy Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 2Q 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing nicely, the financial picture is also vital. This quarter’s release shows that the company has made advances in controlling expenses |
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross ProceedsBURLINGTON, Mass., August 02, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exerci |
OTC Markets Hosts Virtual Investor Presentation with Jeff Frelick, CEO and President of Bone Biologics, and Deina Walsh, CFO, with Brad Sorensen, Senior Analyst at Zacks SCRNASDAQ:BBLG Matt Liteplo: Hello, and welcome to Virtual Investor Conferences. My name is Matt Liteplo, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you have joined us for our next live presentation from Bone Biologics Corp. Brad Sorensen, CFA Senior Equity Research Analyst with Zacks Small Cap Research, will moderate the session. Note that you can |
Life Science Virtual Investor Forum Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4cbVF5U The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download in |
First patients treated in Bone Biologics spinal fusion trialThe multicentre trial will see 30 adults living with degenerative disc disease treated with the company’s NB1 device designed to regenerate bone faster |
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine FusionBURLINGTON, Mass., June 20, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. |